Immune modulation of effector CD4+ and regulatory T cell function by sorafenib in patients with hepatocellular carcinoma

Hepatocellular carcinoma (HCC) is a difficult to treat cancer characterized by poor tumor immunity with only one approved systemic drug, sorafenib. If novel combination treatments are to be developed with immunological agents, the effects of sorafenib on tumor immunity are important to understand. I...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Glavni autori: Cabrera, Roniel, Ararat, Miguel, Xu, Yiling, Brusko, Todd, Wasserfall, Clive, Atkinson, Mark A., Chang, Lung Ji, Liu, Chen, Nelson, David R.
Format: Artigo
Jezik:Inglês
Izdano: Springer-Verlag 2012
Teme:
Original Article
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC3863727/
https://ncbi.nlm.nih.gov/pubmed/23223899
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s00262-012-1380-8
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items